{
  "abstract": "Background\n\nPrognostic biomarkers for risk stratification remain limited in de novo metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen receptor pathway inhibitors (ARPIs). We evaluated baseline serum 25-hydroxyvitamin D [25(OH)D] and developed and externally validated a progression-free survival (PFS) model.Methods\n\nThis multicenter retrospective study included 273 patients initiating ARPI-based therapy between January 2021 and April 2026. Etlik City Hospital formed the training cohort (n = 192; 85 PFS events), and Gazi University and Kütahya City Hospital formed the external validation cohort (n = 81; 27 PFS events). LASSO-penalized Cox regression retained age, ISUP grade group, CHAARTED disease volume, log-transformed PSA, and hemoglobin. Model B added continuous 25(OH)D. Internal validation used 1000 bootstrap resamples. Performance was assessed by the Harrell C-index, time-dependent AUC, and calibration at 1 and 2 years. PFS was the primary endpoint; overall survival analyses were exploratory. The study was not prospectively registered.Results\n\nHigher baseline 25(OH)D was associated with longer PFS in Model B (HR per 10-ng/mL increase, 0.64; 95% CI, 0.49-0.83; P < .001). Adding 25(OH)D improved model fit (likelihood-ratio χ² = 12.71; P < .001) and increased apparent C-index from 0.712 to 0.740. In external validation, C-indices were 0.71 (95% CI, 0.64-0.78) and 0.76 (95% CI, 0.69-0.83), respectively (Δ = 0.05; 95% CI, 0.01-0.10).Conclusions\n\nBaseline 25(OH)D added modest prognostic information beyond clinical factors, with supportive external validation. These findings do not establish treatment-predictive utility or benefit from vitamin D supplementation. Prospective validation is needed before clinical implementation.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Medical Oncology, Etlik City Hospital, Ankara, 06170, Turkey.",
    "Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, 06500, Turkey.",
    "Department of Medical Oncology, Kütahya City Hospital, Kütahya, 43100, Turkey."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Galip Can Uyar",
      "orcid": "0000-0002-0698-777X"
    },
    {
      "affs": [
        0
      ],
      "name": "Kadriye Başkurt",
      "orcid": "0000-0002-6091-730X"
    },
    {
      "affs": [
        1
      ],
      "name": "Orhun Akdoğan",
      "orcid": "0000-0003-0212-1191"
    },
    {
      "affs": [
        0
      ],
      "name": "Enes Yeşilbaş",
      "orcid": "0000-0002-0947-702X"
    },
    {
      "affs": [
        2
      ],
      "name": "Mustafa Ersoy",
      "orcid": "0000-0001-9035-4846"
    },
    {
      "affs": [
        1
      ],
      "name": "Tuba Uğur Tuzcu",
      "orcid": "0000-0002-7750-814X"
    },
    {
      "affs": [
        0
      ],
      "name": "Kadriye Bir Yücel",
      "orcid": "0000-0002-4745-1605"
    },
    {
      "affs": [
        0
      ],
      "name": "Mustafa Altınbaş",
      "orcid": "0000-0002-8024-2362"
    },
    {
      "affs": [
        0
      ],
      "name": "Ömür Berna Çakmak Öksüzoğlu",
      "orcid": "0000-0002-2756-8646"
    },
    {
      "affs": [
        0
      ],
      "name": "Gökşen İnanç İmamoğlu",
      "orcid": "0000-0003-0356-0727"
    },
    {
      "affs": [
        1
      ],
      "name": "Osman Sütcüoğlu",
      "orcid": "0000-0003-3835-2741"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/8wbz9j25ct1xj.bib",
  "cited_by": 0,
  "doi": "10.1093/oncolo/oyag396",
  "fulltext_url": "https://europepmc.org/articles/PMC13680101",
  "id": "8wbz9j25ct1xj",
  "issns": [
    "1083-7159",
    "1549-490X"
  ],
  "landing_url": "https://europepmc.org/article/MED/42836684",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2740|Prostate Cancer Treatment and Research"
    ]
  ],
  "openalex": "W7220717084",
  "pdf_url": "https://europepmc.org/articles/PMC13680101?pdf=render",
  "pmcid": "PMC13680101",
  "pmid": "42836684",
  "published": "2026-10-01",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/8wbz9j25ct1xj.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:10Z",
      "native_id": "MED:42836684",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42836684"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2740|Prostate Cancer Treatment and Research",
      "subfield": "general"
    }
  ],
  "title": "Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation.",
  "title_text": "Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:18:10Z",
  "url": "https://research.draconitic.com/paper/8wbz9j25ct1xj",
  "venue": "The oncologist",
  "versions": []
}